SXTCNasdaqPharmaceutical PreparationsFiscal year ends March 31
China SXT Pharmaceuticals, Inc.
Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 20-F on Jul 1, 2026
$0.11+0.05 (+71.08%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Who owns China SXT Pharmaceuticals's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Ching Choon Hwa | 9,803,920 | 8.45% | 13G (passive) | Jul 29, 2025 |
| Orca Capital AG | 1,112,788 | 9.90% | 13G (passive) | Oct 8, 2026 |
| Foong Soon Hong, Randy | 10,588,240 | 9.12% | 13G (passive) | Jul 29, 2025 |
| Tan Soo Seng | 10,392,160 | 8.95% | 13G (passive) | Jul 29, 2025 |
| Tan Cheng Guan | 10,196,080 | 8.79% | 13G (passive) | Jul 29, 2025 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Feng Felix Zhou | Co-CEO and Director | 4 | 0.00% | Apr 27, 2026 |
| Xiaodong Sean Pan | Chief Financial Officer | – | – | Apr 27, 2026 |
| Lim Sze Beng Simon | Co-Chief Executive Officer | – | – | Apr 27, 2026 |
| Jun Zheng | Director | – | – | Apr 27, 2026 |
| Tong Tony Liu | Director | – | – | Apr 27, 2026 |
| Yong Lip Chee | Director | – | – | Apr 27, 2026 |
| Xiaodong Ji | Director | – | – | Apr 27, 2026 |